NCT00440635View on ClinicalTrials.gov

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

641

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

October 31, 2006

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib, tradename Velcade

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY